4 completed. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Directly Observed Therapy: new trials by email Literature Review of Directly Observed Therapy trials Research Report on Directly Observed Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 150 | 2018-02-02 | 2021-05-18 |
| Directly Observed Therapy for HCV in Chennai, India Sofosbuvir, Pegylated Interferon alfa-2a, Ribavirin - Hepatitis C, Chronic | Phase 2 | Completed | Johns Hopkins Bloomberg School of Public Health | 50 | 2015-09-01 | 2021-04-15 |
| Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy Directly Observed Therapy (DOT), Fluoxetine - HIV Infections, Depression | Phase 2 | Completed | Massachusetts General Hospital | 150 | 2001-01-01 | 2013-11-15 |
| A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation lopinavir/ritonavir, emtricitabine, stavudine - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 402 | 2021-11-01 |
HIV Infections (2) · Hepatitis C, Chronic (2) · Acquired Immunodeficiency Syndrome (1) · Depression (1)
Behavior (4) · Blood-Borne Infections (4) · Communicable Diseases (4) · Health Behavior (4) · Infections (4) · Medication Adherence (4) · Patient Acceptance of Health Care (4) · Patient Compliance (4) · RNA Virus Infections (4) · Treatment Adherence and Compliance (4) · Virus Diseases (4) · Chronic Disease (2) · Digestive System Diseases (2) · Disease Attributes (2) · Flaviviridae Infections (2)
Sofosbuvir (2) · peginterferon alfa-2a (2) · Emtricitabine (1) · Fluoxetine (1) · Lopinavir (1) · Ribavirin (1) · Stavudine (1) · Tenofovir (1) · daclatasvir (1)
Johns Hopkins Bloomberg School of Public Health (2) · Massachusetts General Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
India (2) · United States (2) · Puerto Rico (1) · South Africa (1)
Charles Flexner, MD (1) · David R. Bangsberg, MD, MPH (1) · Donna Mildvan, MD (1) · Shruti Mehta, PhD, MPH (1) · Sunil S Solomon, MBBS, PhD, MPH (1)
PMID 19597072, PMID 20192725, PMID 27590273, PMID 28719029
R01DA026727 (2), R01MH063011 (1)